Covalon Technologies Ltd. (CVALF)
USD 2.42
(-1.63%)
USD 2.42
(-1.63%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -4.48 Million CAD | 50.47% |
| 2022 | -9.14 Million CAD | -1190.52% |
| 2021 | 838.34 Thousand CAD | 113.76% |
| 2020 | -6.09 Million CAD | 26.14% |
| 2019 | -8.24 Million CAD | -609.92% |
| 2018 | 1.61 Million CAD | -10.71% |
| 2017 | 1.81 Million CAD | 161.1% |
| 2016 | -2.96 Million CAD | -291.12% |
| 2015 | -758.15 Thousand CAD | -131.03% |
| 2014 | 2.44 Million CAD | 342.53% |
| 2013 | -1 Million CAD | 72.53% |
| 2012 | -3.66 Million CAD | -1.47% |
| 2011 | -3.61 Million CAD | -76.86% |
| 2010 | -2.04 Million CAD | 58.07% |
| 2009 | -4.87 Million CAD | -30.31% |
| 2008 | -3.74 Million CAD | -9.7% |
| 2007 | -3.41 Million CAD | -46.79% |
| 2006 | -2.32 Million CAD | -26.23% |
| 2005 | -1.84 Million CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 1.47 Million CAD | 2.29% |
| 2024 Q1 | -1.47 Million CAD | 48.61% |
| 2024 Q2 | 1.48 Million CAD | 200.76% |
| 2023 Q2 | -721.78 Thousand CAD | -102.83% |
| 2023 Q4 | -2.86 Million CAD | -387.24% |
| 2023 Q3 | -587.64 Thousand CAD | 18.59% |
| 2023 FY | -4.52 Million CAD | 50.47% |
| 2023 Q1 | -355.85 Thousand CAD | 91.2% |
| 2022 Q3 | -1.57 Million CAD | 34.93% |
| 2022 Q4 | -4.04 Million CAD | -156.52% |
| 2022 Q2 | -2.42 Million CAD | -121.31% |
| 2022 Q1 | -1.09 Million CAD | -124.55% |
| 2022 FY | -9.14 Million CAD | -1190.52% |
| 2021 Q2 | 539.05 Thousand CAD | 312.79% |
| 2021 Q1 | -253.32 Thousand CAD | 87.21% |
| 2021 Q3 | 1.18 Million CAD | 119.14% |
| 2021 FY | 838.34 Thousand CAD | 113.76% |
| 2021 Q4 | -487.77 Thousand CAD | -141.29% |
| 2020 Q4 | -1.97 Million CAD | -480.94% |
| 2020 FY | -6.09 Million CAD | 26.14% |
| 2020 Q2 | -3.68 Million CAD | -288.09% |
| 2020 Q1 | -948.99 Thousand CAD | 71.1% |
| 2020 Q3 | 519.74 Thousand CAD | 114.11% |
| 2019 Q3 | -3.27 Million CAD | -2761.58% |
| 2019 Q2 | -114.58 Thousand CAD | 92.71% |
| 2019 Q1 | -1.57 Million CAD | -151.35% |
| 2019 FY | -8.24 Million CAD | -609.92% |
| 2019 Q4 | -3.28 Million CAD | -0.15% |
| 2018 Q1 | 523.34 Thousand CAD | 101.8% |
| 2018 Q2 | -479.08 Thousand CAD | -191.54% |
| 2018 Q3 | 2.19 Million CAD | 558.89% |
| 2018 Q4 | -625.08 Thousand CAD | -128.43% |
| 2018 FY | 1.61 Million CAD | -10.71% |
| 2017 Q2 | 473.47 Thousand CAD | -12.81% |
| 2017 Q3 | 541.28 Thousand CAD | 14.32% |
| 2017 Q4 | 259.33 Thousand CAD | -52.09% |
| 2017 FY | 1.81 Million CAD | 161.1% |
| 2017 Q1 | 543.04 Thousand CAD | 125.35% |
| 2016 Q3 | -124 Thousand CAD | 87.84% |
| 2016 Q2 | -1.02 Million CAD | -417.08% |
| 2016 Q1 | 321.71 Thousand CAD | 142.85% |
| 2016 FY | -2.96 Million CAD | -291.12% |
| 2016 Q4 | -2.14 Million CAD | -1627.26% |
| 2015 Q2 | 305.01 Thousand CAD | 252.08% |
| 2015 Q4 | -750.87 Thousand CAD | -573.3% |
| 2015 FY | -758.15 Thousand CAD | -131.03% |
| 2015 Q3 | -111.52 Thousand CAD | -136.56% |
| 2015 Q1 | -200.56 Thousand CAD | 78.43% |
| 2014 Q2 | 448.14 Thousand CAD | -85.75% |
| 2014 Q4 | -929.78 Thousand CAD | -324.88% |
| 2014 Q1 | 3.14 Million CAD | 2451.95% |
| 2014 FY | 2.44 Million CAD | 342.53% |
| 2014 Q3 | -218.83 Thousand CAD | -148.83% |
| 2013 FY | -1 Million CAD | 72.53% |
| 2013 Q4 | 123.19 Thousand CAD | -47.43% |
| 2013 Q3 | 234.32 Thousand CAD | 141.53% |
| 2013 Q2 | -564.2 Thousand CAD | 29.54% |
| 2013 Q1 | -800.74 Thousand CAD | 46.56% |
| 2012 Q1 | -815.59 Thousand CAD | 37.44% |
| 2012 FY | -3.66 Million CAD | -1.47% |
| 2012 Q4 | -1.49 Million CAD | -102.6% |
| 2012 Q3 | -739.53 Thousand CAD | -20.38% |
| 2012 Q2 | -614.33 Thousand CAD | 24.68% |
| 2011 Q2 | -447.72 Thousand CAD | 30.38% |
| 2011 FY | -3.61 Million CAD | -76.86% |
| 2011 Q1 | -643.06 Thousand CAD | 41.82% |
| 2011 Q4 | -1.3 Million CAD | -6.85% |
| 2011 Q3 | -1.22 Million CAD | -172.52% |
| 2010 Q1 | -338.45 Thousand CAD | 59.92% |
| 2010 FY | -2.04 Million CAD | 58.07% |
| 2010 Q4 | -1.1 Million CAD | -248.33% |
| 2010 Q3 | -317.3 Thousand CAD | -12.2% |
| 2010 Q2 | -282.8 Thousand CAD | 16.44% |
| 2009 FY | -4.87 Million CAD | -30.31% |
| 2009 Q4 | -844.45 Thousand CAD | 29.7% |
| 2009 Q3 | -1.2 Million CAD | 18.93% |
| 2009 Q2 | -1.48 Million CAD | -2.12% |
| 2009 Q1 | -1.45 Million CAD | -40.83% |
| 2008 Q2 | -1.28 Million CAD | -29.27% |
| 2008 Q3 | -779.92 Thousand CAD | 39.12% |
| 2008 FY | -3.74 Million CAD | -9.7% |
| 2008 Q4 | -1.03 Million CAD | -32.1% |
| 2008 Q1 | -991 Thousand CAD | 23.02% |
| 2007 Q1 | -452.15 Thousand CAD | 38.9% |
| 2007 Q3 | -1.06 Million CAD | -74.25% |
| 2007 Q4 | -1.28 Million CAD | -21.29% |
| 2007 Q2 | -609.13 Thousand CAD | -34.72% |
| 2007 FY | -3.41 Million CAD | -46.79% |
| 2006 FY | -2.32 Million CAD | -26.23% |
| 2006 Q3 | -569.2 Thousand CAD | -0.13% |
| 2006 Q2 | -568.46 Thousand CAD | -27.62% |
| 2006 Q1 | -445.43 Thousand CAD | 54.36% |
| 2006 Q4 | -740.03 Thousand CAD | -30.01% |
| 2005 Q3 | -339.11 Thousand CAD | -0.05% |
| 2005 Q2 | -338.95 Thousand CAD | -91.7% |
| 2005 Q4 | -975.96 Thousand CAD | -187.8% |
| 2005 FY | -1.84 Million CAD | 0.0% |
| 2005 Q1 | -176.81 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 93.747% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 191.339% |
| SQZ Biotechnologies Company | -75.82 Million USD | 94.08% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 74.847% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 105.484% |
| Mesoblast Limited | -84.14 Million USD | 94.665% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -192.252% |
| Genus plc | 6.4 Million USD | 170.143% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 146.078% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -381.988% |
| Marizyme, Inc. | -34.08 Million USD | 86.83% |
| ContraFect Corporation | -56.88 Million USD | 92.109% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 46.238% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 1.44% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -220.197% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -57.486% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -63.192% |
| MultiCell Technologies, Inc. | -722.81 USD | -620967.362% |
| Accustem Sciences Inc. | -3.74 Million USD | -19.825% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 92.39% |
| EV Biologics, Inc. | -483.06 Thousand USD | -829.309% |
| Q BioMed Inc. | -3.44 Million USD | -30.285% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 226.812% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -1052.331% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -70.851% |
| Biomind Labs Inc. | -1 Million USD | -344.644% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | -4.87 Million USD | 8.001% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 32.474% |
| Skye Bioscience, Inc. | -13.67 Million USD | 67.165% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -125.985% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -14887.77% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 11.009% |
| IMV Inc. | -38.67 Million USD | 88.392% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 71.713% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -132.284% |
| GB Sciences, Inc. | -1.42 Million USD | -216.023% |
| Alpha Cognition Inc. | -9.7 Million USD | 53.747% |
| HST Global, Inc. | -140.9 Thousand USD | -3085.886% |
| CSL Limited | 3.7 Billion USD | 100.121% |
| Halberd Corporation | -75.05 Thousand USD | -5881.528% |
| Enzolytics Inc. | -2.14 Million USD | -108.914% |
| Resverlogix Corp. | -12.74 Million USD | 64.788% |
| Affymax, Inc. | -15.04 Million USD | 70.164% |
| SYBLEU INC | -149.18 Thousand USD | -2909.208% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -41.69% |
| argenx SE | -425.04 Million USD | 98.944% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 91.913% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -329.994% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -184.239% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -31.84% |
| AVAX Technologies, Inc. | 6.69 Million USD | 167.073% |
| Zenith Capital Corp. | -8.94 Million USD | 49.803% |
| Genscript Biotech Corporation | -415.79 Million USD | 98.92% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -25668.538% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -82.833% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -2517.427% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 91.834% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -54.731% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -356.189% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -140.786% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -257.415% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -123.924% |
| BioStem Technologies, Inc. | -7.77 Million USD | 42.291% |
| ONE Bio Corp. | 13.68 Million USD | 132.812% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -2373.558% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -236.156% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -299.068% |
| Agentix Corp. | -1.37 Million USD | -227.255% |
| LadRx Corporation | -3.82 Million USD | -17.405% |
| Cell Source, Inc. | -4.32 Million USD | -3.787% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -980.473% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -553.488% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -553.488% |
| NovAccess Global Inc. | -2.46 Million USD | -81.985% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -53.767% |
| Itoco Inc. | -919.14 Thousand USD | -388.406% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -5.915% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -301.174% |
| Kadimastem Ltd | -3.04 Million USD | -47.657% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -1615.205% |
| CytoDyn Inc. | -18.05 Million USD | 75.14% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -17735.268% |
| Mobile Lads Corp. | -554.55 Thousand USD | -709.51% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1939.794% |
| Qrons Inc. | -643.67 Thousand USD | -597.421% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -694.927% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -2.22 Million USD | -101.318% |
| Rebus Holdings, Inc. | -664 Thousand USD | -576.075% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -147.156% |
| International Stem Cell Corporation | -663 Thousand USD | -577.095% |
| Bioxytran, Inc. | -3.82 Million USD | -17.512% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -8427.996% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -21970.487% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 87.622% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -177.45% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -510.074% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -44.299% |
| Neutra Corp. | -229.48 Thousand USD | -1856.17% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 74.405% |
| PureTech Health plc | -146.19 Million USD | 96.929% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 79.112% |
| IXICO plc | -1.43 Million USD | -212.396% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 52.701% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 96.315% |
| CSL Limited | 3.81 Billion USD | 100.118% |
| Cellectis S.A. | -108.85 Million USD | 95.876% |